Edwards Lifesciences Corporation
EW NYSEHealthcare ★★★★★Latest Earnings
Date
Jul 23, 2026
ET
EPS Est.
0.74
EPS Actual
0.78
Revenue Est.
$1.7B
Revenue Actual
$1.74B
Next Earnings Report
Date
Oct 29, 2026 · Thu
Time
After-market
Fiscal Period
FY2026 Q3
EPS Est.
0.73
Revenue Est.
$1.68B
Company Overview
Edwards Lifesciences Corporation (ticker EW) is listed on NYSE with a market cap of about $51.7B. Its next earnings report (FY2026 Q3) is expected on Oct 29, 2026 (ET), After-market, with consensus EPS of 0.73. In the last 15 reported quarters, EPS beat consensus estimates 12 times.
Actual EPS TrendRecently15Term · Jan 31, 2023 → Jul 23, 2026
Jan 31, 2023Range: 0.58 ~ 0.78Jul 23, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 23, 2026 | -- | 0.74 | 0.78 | $1.7B | $1.74B |
| Apr 23, 2026 | -- | 0.73 | 0.78 | $1.6B | $1.65B |
| Feb 10, 2026 | -- | 0.62 | 0.58 | $1.55B | $1.57B |
| Oct 30, 2025 | -- | 0.60 | 0.67 | $1.5B | $1.55B |
| Jul 24, 2025 | -- | 0.62 | 0.67 | $1.49B | $1.53B |
| Apr 23, 2025 | -- | 0.60 | 0.64 | $1.4B | $1.41B |
| Feb 11, 2025 | -- | 0.55 | 0.59 | $1.36B | $1.39B |
| Oct 24, 2024 | -- | 0.67 | 0.67 | $1.54B | $1.35B |
| Jul 24, 2024 | -- | 0.69 | 0.70 | $1.65B | $1.39B |
| Apr 25, 2024 | -- | 0.64 | 0.66 | $1.57B | $1.6B |
| Feb 6, 2024 | -- | 0.64 | 0.64 | $1.49B | $1.53B |
| Oct 25, 2023 | -- | 0.59 | 0.59 | $1.48B | $1.48B |
| Jul 26, 2023 | -- | 0.65 | 0.66 | $1.5B | $1.53B |
| Apr 26, 2023 | -- | 0.61 | 0.62 | $1.39B | $1.46B |
| Jan 31, 2023 | -- | 0.61 | 0.64 | $1.33B | $1.35B |
Original Filings (SEC)
10-Q2026-08-04 ↗
8-K2026-07-23 ↗
8-K2026-05-08 ↗
10-Q2026-05-06 ↗
8-K2026-05-04 ↗
8-K2026-04-23 ↗
10-K2026-02-25 ↗
8-K2026-02-10 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
